Glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA tirzepatide [16,17] has been shown to significantly reduce body weight in placebo-controlled studies involving patients with type 2 diabetes and obesity [16-19], with findings indicating improvement in MASH and liver fibrosis biomarkers in this population [20,21]. Therefore, switching from GLP-1RAs to tirzepatide may benefit patients with inadequate MASLD management despite using GLP-1RAs. Here, GIP is linked to obesity disorder.